Open AccessExpression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast‐conserving surgery: a long‐term follow‐up of the SweBCG91‐RT randomised trial
Author(s) -
Sjöström Martin,
Veenstra Cynthia,
Holmberg Erik,
Karlsson Per,
Killander Fredrika,
Malmström Per,
Niméus Emma,
Fernö Mårten,
Stål Olle
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12803
Subject(s) - medicine , hepatocyte growth factor , clinical endpoint , tissue microarray , hazard ratio , breast cancer , radiation therapy , oncology , radioresistance , breast conserving surgery , protein kinase b , immunohistochemistry , pathology , randomized controlled trial , cancer , receptor , mastectomy , apoptosis , biology , confidence interval , biochemistry
We investigated the importance of HGF, pMET and pAkt for the risk of ipsilateral breast tumour recurrence after adjuvant radiotherapy in primary breast cancer in tumours from the SweBCG91‐RT randomised trial. Low levels of HGF and pMet in the tumour cell cytoplasm and high levels of pAkt in the tumour cell nucleus are associated with a larger benefit from RT, indicating that these proteins may be used as biomarkers or treatment targets.